Bevacizumab, Idarubicin, and Cytarabine in Treating Patients With Blast Phase Chronic Myelogenous Leukemia

• Status: Terminated
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This phase II trial is to see if combining bevacizumab with idarubicin and cytarabine works better in treating patients who have blast phase chronic myelogenous leukemia. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may be an effective treatment for blast phase chronic myelogenous leukemia

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute (NCI)
• Treatments: Antibodies; Antibodies, Monoclonal; Antineoplastic Agents, Immunological; Bevacizumab; Cytarabine; Idarubicin; Immunoglobulins

Criteria

Inclusion Criteria:

• Diagnosis of Philadelphia chromosome-positive blastic phase chronic myelogenous leukemia (CML), defined by 1 of the following:

• At least 30% blasts in peripheral blood and/or bone marrow

• Presence of extramedullary disease

• Performance status - Zubrod 0-2

• At least 8 weeks

• No prior coagulopathies

• Bilirubin no greater than 1.5 mg/dL

• INR less than 2

• PTT no greater than 60 seconds

• Creatinine no greater than 1.5 mg/dL

• Creatinine clearance at least 60 mL/min

• No nephrotic syndrome

• No uncontrolled hypertension

• No New York Heart Association class II-IV heart disease

• No prior thrombotic events

• LVEF ≥ 50%

• Not pregnant or nursing

• Fertile patients must use effective contraception

• No more than 2 prior chemotherapy regimens (no more than 1 regimen containing cytarabine) for CML in blast crisis

• Prior hydroxyurea allowed

• Prior imatinib mesylate allowed

• At least 10 days since prior anticoagulants

• No concurrent anticoagulants